Genocea Biosciences, Inc. (NASDAQ:GNCA) has scheduled a conference call for 29th October 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.genocea.com
Earnings Expectation
Genocea Biosciences, Inc. is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, GNCA is expected to report 3Q20 loss of $ 0.24 per share. For the full year, analysts anticipate top line of $ 0.90 million, while looking forward to loss of $ 1.21 per share bottom line.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to recall a patients pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify neoantigens and antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase 1/2a clinical trial, designed to direct a patients immune system to attack tumor.
